Why is this debate still going on at all?

The question between different types of physician as to whether radiation therapy or surgery is “better” for the first-line, curative treatment of localized prostate cancer has now been debated (over and over) for more than 40 years. … READ MORE …

How long is long enough? Length of follow-up on clinical trials for primary treatments

Many of us are faced with the difficulty of choosing a primary therapy based on data from clinical trials with follow-up shorter than our life expectancy. How can we know what to expect in 20 or 30 years? … READ MORE …

The value of the PCTRF comparative outcomes data

The “New” Prostate Cancer InfoLink wants to be clear for our readers that we are significantly less enthusiastic than others about some of the information being offered to patients, clinicians, and payers through the web site of an organization known as the Prostate Cancer Treatment Research Foundation (PCTRF). … READ MORE …

Accuracy and relevance of clinical stage in diagnosis and prognosis of localized prostate cancer

According to a new report from the University of California, San Francisco (to be published in Cancer this week), clinical staging errors may — at least in part — underlie the fact that the researchers were unable to demonstrate a clear link between clinical stage and risk for prostate cancer recurrence in patients initially diagnosed with localized prostate cancer. … READ MORE …

The relevance of clinical stage in diagnosis of localized prostate cancer today

The staging systems used by clinicians and pathologists for assignment of the stage of prostate cancer were all developed more than 20 years ago, and have seen only relatively minor adjustments since the introduction of the PSA test. … READ MORE …